Galena Announces Partnership With Teva; Jazz Pharma Announces Issuance of Additional Xyrem Patent Print E-mail
By Staff and Wire Reports   
Tuesday, 04 December 2012 19:31
Below is a look at some of the headlines for companies that made news in the healthcare sector on December 4, 2012.

Galena Biopharma, (NASDAQ: GALE)
, a biotechnology company focused on developing innovative, targeted oncology treatments, today announced it has signed an agreement with a subsidiary of Teva Pharmaceutical Industries Limited for the commercialization of NeuVax™ (nelipepimut-S or E75) in Israel.

"This agreement is the first piece of our global commercialization strategy," said Mark Ahn, Ph.D., President and Chief Executive Officer, Galena Biopharma. "Teva is a world-class pharmaceutical company and a major pharmaceutical company in Israel. We look forward to their valuable financial support towards our development goals in Israel, as well as market leadership for NeuVax commercialization in the region."

Under the agreement, Teva Israel will assume responsibility for regulatory registration in Israel, provide financial support for local development, and will commercialize the product in the region. Specific financial terms were not disclosed, but the agreement allows for significant royalty payments to Galena Biopharma on future sales.


======


Jazz Pharmaceuticals (NASDAQ: JAZZ)
announced that the United States Patent and Trademark Office has issued a patent related to the use of Xyrem® (sodium oxybate) oral solution for the treatment of narcolepsy, titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy." The new patent, number 8,324,275, will be submitted for listing in the FDA's Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book).

"Our intellectual property, including the patent issued today, reflects the company's continued commitment to the further understanding of Xyrem and to supporting its safe and effective use," stated Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.

In addition to the newly issued patent, ten other U.S. patents have previously been issued related to Xyrem's stable and microbially resistant formulation, its manufacturing process, and its method of use, including its restricted distribution system. The new patent, which will expire in December 2019, would be the ninth patent referencing Xyrem to be listed in the Orange Book. The listed patents expire at various times from 2019 to 2024.

Xyrem is the only product approved by the United States Food and Drug Administration for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy.


Also Tuesday:


Amarantus Bioscience, Inc. (OTCQB: AMBS)
, a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it has appointed former Super Bowl Champion Toi Cook to its Board of Advisors.

Bioheart Inc. (OTCQB: BHRT)
previously announced that its cGMP facility would be utilized by Stemlogix to help promote regenerative medicine for the veterinary market.

RetailInvestorConferences.com is pleased to announce that BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, will present at RetailInvestorConferences.com.

The first patient has been enrolled in a Boston Scientific Corporation (NYSE: BSX) study comparing the WallFlex®  Biliary RX Fully Covered self-expanding metal stent (SEMS) to plastic stents for the treatment of benign bile duct strictures caused by chronic pancreatitis.  

eHealth, Inc. (NASDAQ: EHTH)
, parent company of entities that operate PlanPrescriber.com and eHealthMedicare.com, published answers to the five questions most commonly asked by Medicare beneficiaries during Medicare's Annual Enrollment Period (AEP), which began on October 15, 2012 and runs through December 7, 2012.

Edwards Lifesciences Corporation (NYSE: EW)
, the global leader in the science of heart valves and hemodynamic monitoring, today will provide investors with information on the initiatives expected to result in strong double-digit sales and earnings growth in 2013.

EntreMed, Inc. (Nasdaq: ENMD)
, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that preclinical results for its compound 2-methoxyestradiol (2ME2) were published on line in this week's Early Edition of Proceedings of the National Academy of Sciences (PNAS).

ExamWorks Group, Inc. (NYSE: EXAM)
, a leading provider of independent medical examinations (IMEs), peer reviews, bill reviews and related services, announced today that the Company is increasing guidance for the fourth quarter and full year 2012 to more accurately reflect the impact from Hurricane Sandy and performance during the first two months of the quarter.

Given Imaging Ltd. (NASDAQ: GIVN)
, a world leader in GI medical devices, and maker of PillCam® capsule endoscopy, today announced the results of Crohn's Voices, an online survey of Crohn's patients about their understanding of their condition, their approach to managing their condition with their physician, and what matters most to them in a clinical test of disease activity.

Health Sciences Group Inc. (PINKSHEETS: HESG)
announced today that it has subscribed to the OTC Disclosure Service to provide regular disclosures and transparency to investors.

Demonstrating its growing leadership as a distributor of mobile health technologies, Ingram Micro Inc. (NYSE: IM) today announced it has signed and executed a strategic agreement with Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated, to distribute its 2net™ Hub worldwide.

InspireMD, Inc. (OTC BB: NSPR)
("Inspire" or the "Company"), the developer of the MGuard™ Embolic Protection Stent (EPS), will sponsor a satellite symposium on December 4th at the ICI, Innovations in Cardiovascular Innovation, Meeting at the David Intercontinental Hotel, Tel-Aviv.  

MetaStat, Inc. (OTCBB: MTST)
, a life science company focused on understanding and treating systemic metastasis, today announced that John S. Condeelis, Ph.D., Chairman of MetaStat's Scientific Advisory Board, and Joan Jones, M.D., a member of MetaStat's Clinical Advisory Board, will be presenting data on the Company's licensed metastatic breast cancer markers at the CTRC-AACR 2012 San Antonio Breast Cancer Symposium on December 4-8, 2012, in San Antonio, Texas.

MYOS Corporation (OTCBB: MYOS)
, a company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance, announced today that the Company's highly regarded MYO-T12® formulation is now available in the product MYO-X™ at retail powerhouse GNC, through MYOS' premier distributor, MHP.

Quest Diagnostics (NYSE: DGX)
, the world's leading provider of diagnostic information services, today announced that the specimen biorepository of its Quest Diagnostics Clinical Trials business, a leader in laboratory testing services to advance drug discovery and development, has been accredited by the College of American Pathologists (CAP), the international laboratory accrediting organization.

University General Health System, Inc. (OTCQB: UGHS)
, a diversified, integrated multi-specialty health care delivery system, today announced that it has executed an agreement to purchase South Hampton Community Hospital in Dallas, Texas, effective December 31, 2012.

UV Flu Technologies, Inc. (OTCBB: UVFT)
(the "Company") is pleased to announce that it has signed a distribution agreement with the Davison Product Group, LLC, aka DPG Distribution, of Heathrow, Florida.

VentriPoint Diagnostics (TSX VENTURE:VPT) (OTCQX:VPTDF)
will be exhibiting at the Annual Meeting of EUROECHO & other Imaging Modalities 2012 from December 5th to 8thin Athens, Greece. VentriPoint is focused on imaging the right heart using low-cost ultrasound to make right-heart diagnostics faster and more cost effective.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter